Braftovi Capsule
NDC Package 70255-025-01

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Other Packages
    3. Frequently Asked Questions

Package Information

Braftovi (encorafenib) capsules is encorafenib is used to treat certain types of cancer (such as melanoma skin cancer, cancer in the colon or rectum). This formulation utilizes a capsule delivery system. Marketed by Array Biopharma Inc., this product is identified by NDC 70255-025 and is authorized under FDA application NDA210496.

Identification & Billing

NDC Package Code
70255-025-01
Package Description
2 BOTTLE in 1 CARTON / 90 CAPSULE in 1 BOTTLE (70255-025-02)
Product Code
70255-025
11-Digit Billing Format
70255002501
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
Units Per Package
2 EA
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Braftovi
Non-Proprietary Name
Encorafenib
Substance Name
Encorafenib
Dosage Form
Capsule - A solid oral dosage form consisting of a shell and a filling. The shell is composed of a single sealed enclosure, or two halves that fit together and which are sometimes sealed with a band. Capsule shells may be made from gelatin, starch, or cellulose, or other suitable materials, may be soft or hard, and are filled with solid or liquid ingredients that can be poured or squeezed.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
ENCORAFENIB 75 mg/1
Usage Information
Encorafenib is used to treat certain types of cancer (such as melanoma skin cancer, cancer in the colon or rectum). Encorafenib belongs to a class of drugs known as kinase inhibitors. It works by slowing or stopping the growth of cancer cells.

Regulatory & Marketing

Labeler Name
Array Biopharma Inc.
Product Type
Human Prescription Drug
FDA Application #
NDA210496
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
06-27-2018
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (70255-025). Click a package code to view its specific billing and regulatory data.

70255-025-03
2 BOTTLE in 1 CARTON / 60 CAPSULE in 1 BOTTLE (70255-025-04)
70255-025-05
90 CAPSULE in 1 BOTTLE
70255-025-06
60 CAPSULE in 1 BOTTLE

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 70255-025-01 identifies a specific commercial package of 2 bottle in 1 carton / 90 capsule in 1 bottle (70255-025-02) of Braftovi, a human prescription drug labeled by Array Biopharma Inc.. This product is billed for "EA" each discreet unit and contains an estimated amount of 2 billable units per package. This capsule is formulated for oral use and contains encorafenib as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Array Biopharma Inc. on June 27, 2018. The current certification is valid through December 31, 2027.

What are the primary indications for this medication?

Encorafenib is used to treat certain types of cancer (such as melanoma skin cancer, cancer in the colon or rectum). Encorafenib belongs to a class of drugs known as kinase inhibitors. It works by slowing or stopping the growth of cancer cells.

How is this Array Biopharma Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 70255002501. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 2 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
70255-025-01
11-Digit CMS (5-4-2)
70255-0025-01

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.